CompletedPhase 2

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

United States47 participantsStarted 2020-11-21

Plain-language summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years of age of either gender and any race * Able to provide written informed consent and sign the HIPAA form * Willing and able to follow all instructions and attend all study visits Exclusion Criteria: * Able and willing to avoid all disallowed medications during washout and study period

What they're measuring

Ocular Itching as Measured by Self-reported Numerical Scales

Timeframe: 16 hours, 8 hours, and 15 minutes post-treatment

Conjunctival Redness as Measured by Investigator Assessed Numerical Scales

Timeframe: 16 hours, 8 hours, and 15 minutes post-treatment

Trial details

NCT IDNCT04622345

SponsorVanda Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-05-22

Results submitted2024-03-19

View on ClinicalTrials.gov More Allergic Conjunctivitis trials